WO1997049669A1 - Verbindungen, die mit metallen komplexe bilden können - Google Patents
Verbindungen, die mit metallen komplexe bilden können Download PDFInfo
- Publication number
- WO1997049669A1 WO1997049669A1 PCT/EP1996/002796 EP9602796W WO9749669A1 WO 1997049669 A1 WO1997049669 A1 WO 1997049669A1 EP 9602796 W EP9602796 W EP 9602796W WO 9749669 A1 WO9749669 A1 WO 9749669A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- myxochelin
- nitrile
- dibenzyloxybenzoyl
- compounds
- compound according
- Prior art date
Links
- 0 *C(CCNC(c1cccc(O)c1O)=O)NC(c1cccc(O)c1O)=O Chemical compound *C(CCNC(c1cccc(O)c1O)=O)NC(c1cccc(O)c1O)=O 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/60—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
- C07C255/43—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms the carbon skeleton being further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B57/00—Other synthetic dyes of known constitution
- C09B57/10—Metal complexes of organic compounds not being dyes in uncomplexed form
Definitions
- the present invention relates to a compound of the general formula according to claim 1, an iron complex of this compound according to claim 3, a process for the preparation of the compounds according to claim 4, a conjugate according to claim 5, a medicament according to claim 6, a use of the invention Compounds according to claim 7, a method for complexing metal ions and a use according to claim 9.
- the present invention therefore relates to compounds of the general formula I.
- R -CH 2 -NH-C0- (2,3-dihydroxiphenyl), CN or -CH 2 -NH 2
- the absolute configuration at C-2 can be both S and R and n is a natural number of 1 to 5.
- Myxochelin C (D, L) -1, 2, 7-triamino-tris- [N 1 , N 2 , N 7 - (2, 3-dihydroxy-benzoyl)] -heptane (myxochelin F).
- the compounds according to the invention can be prepared according to the invention by a process in which starting from the amides of the amino acids lysine, ornitine or 2,3-diaminopropionic acid is reduced to the corresponding triamines using a complex hydride.
- the triamines formed are converted to the corresponding triamides using known coupling methods in peptide chemistry with protected 2,3-dihydroxybenzoic acids.
- the triamides obtained are converted by hydrogenolysis into the compounds according to the invention of the general formula (I).
- Myxochelin C can be produced from L-lysinamide using known methods using DCC / HOBt coupling.
- the benzyl-protected 2,3-dihydroxybenzoic acid is bound amidically to the two NH 2 groups, the primary amide is converted into the nitrile by means of crystalline triphosgene, the nitrile is reduced to the primary amine by means of sodium borohydride reduction with the aid of cobalt chloride Structure 6 leads.
- Figure 1 shows the reaction sequence to myxochelin B.
- Figure 2 shows the reaction sequence of the compound
- Compound 6 can be coupled into the 6-fold benzyl-protected triamide by further coupling using DCC / HOBt and an equivalent of benzyl-protected 2,3-dihydroxybenzoic acid
- compound 7 can also be obtained from L-lysinamide after reduction with lithium aluminum hydride to 1,2,6-triaminohexane and reaction of the triamine with three equivalents of the bisbenzyl-protected 2,3-dihydroxybenzoic acid.
- the compounds according to the invention with a siderophoric structure are suitable for being taken up by bacteria. They overcome the bacterial cell wall.
- the compounds R-4 and 5 are introduced by the bacteria in an active transport process. This opens up the possibility of specifically introducing desired substances into such bacteria.
- These can be, for example, pharmacologically or biologically active compounds, such as pharmaceuticals, for example antibiotics, etc.
- they may also have higher molecular structures, for example nucleic acids which are able to transform the corresponding bacterium in this way, or structures of antibodies which determine Recognize, block or otherwise modify bacterial structures.
- the compounds to be introduced into the cell can be covalently attached, for example, to certain functional groups of the compounds according to the invention and then brought into the cell of the bacterium.
- the covalent bond mentioned can also be made unstable, so that this covalent bond is released again by intracellular processes and the active substance is then present in its free form in the cell.
- the advantage of such a coupling is that the active ingredients are brought specifically to the site of action can, so that increased active concentrations can be lowered and thus the risk of side effects can be reduced.
- the conjugates according to the invention can also be used for the production of corresponding medicaments.
- the compounds according to the invention can be used as pharmaceuticals, it being advisable to provide an effective amount of one of the compounds of the formula I or their mixtures with pharmaceutical auxiliaries and / or carriers.
- the choice of aids is based, among other things, on galenical considerations, which in turn may depend on the type of application of the drugs. In principle, it is possible to apply the compounds in dissolved or solid form in appropriate dosage forms.
- the medicaments can be used in particular in therapeutic approaches in which the diseases are caused by defective metal ion metabolism. This can be indicated in particular in the event of an iron or aluminum metabolism error.
- the pharmaceuticals according to the invention complex the metal ions, in particular iron or aluminum ions, which can then be removed from a cell.
- the compounds according to the invention are suitable as antibacterial or antiviral substances.
- the medicaments according to the invention can therefore be used for the treatment of bacterial and / or viral infections.
- the medicaments according to the invention can also be used for parasitic diseases.
- the medicament according to the invention can also be used as medicament in a form loaded with metal ions.
- the medicament according to the invention can remove iron and aluminum in various diseases of humans or animals, e.g. in hemosiderosis or thalassemia or also in Alzheimer's disease, in its metal ion-free form.
- a suitable dosage of the medicament according to the invention can be determined by the person skilled in the art by known tests.
- the medicament according to the invention can also be used for tumor treatment. Iron complexes are thus able to generate oxygen radicals which can attack tumors in particular.
- a method using the uses according to the invention relates to the complexation of metal ions.
- the metal ion-containing solution is brought into direct contact with solutions of the compounds according to the invention or the compounds according to the invention themselves.
- This method is therefore suitable for complexing, characterizing and / or removing metals from corresponding solutions containing these metal ions.
- Radioactive metal ions can also be complexed with the compounds according to the invention. This can serve as a starting point for the enrichment of radioactive isotopes and can be used in an analogous manner for the removal of radioactive isotopes.
- the compounds according to the invention can be used for the analysis of bacteria.
- the presence of pathogenic enterobacteria can be quickly analyzed.
- samples contaminated with pathogenic enterobacteria are incubated in an iron deficiency medium.
- the dark-colored residue is used to separate residual catalyst and metal complexes, which had already formed from traces of metals in the solvents used, in approx. 1 ml of a solution of dichloromethane and 10% methanol, which was previously removed using Chelex 100 to remove Traces of iron were filtered, taken up and applied via a small Pasteur pipette filled with silica gel (100 mg). 1 is eluted from this mini column with a further approx. 10 ml of the solvent, the solution is then freed from the solvent under an oil pump vacuum, 1 crystallizing out in white plates.
- the enantiomerically pure D- and L-ornitinamides can be used to prepare the compound which is shorter by one CH 2 group.
- the enantiomerically pure 2, 3-diaminopropionic acid amides can be used to prepare the chelators which are shorter by three CH 2 groups.
- the following examples relate to the siderophore Myxochelin- C- nitrile (2.) And a method for its preparation.
- the following examples relate to myxochelin D-nitrile (3_) and a process for its production.
- 3_ becomes - as for 2 .
- 3_a is characterized as follows:
- the following example relates to myxochelin D R -nitrile R-3, and a process for its preparation which follows the same route as described for 3_.
- the precursor R-3a shows the same spectroscopic properties as 3_a, but has a rotation value of:
- R-3a 48 mg are hydrogenated under standard conditions at normal pressure. After filtering off over kieselguhr and concentrating i.V. 22 mg (88.7%) of R-3 are obtained. See the description for R-3 for the spectroscopic properties.
- the following example relates to the enantiomer of the natural product myxochelin B, the myxochelin B R (R-4) and a process for its preparation.
- the starting point is R-2b, the spectroscopic properties of which, with the exception of the rotational value, are the same as for . 2 B are (W. Trowitzsch-Kienast, H. Irschik, V. Wray, H. Reichen ⁇ bach, G. Höfle, Liebigs Ann. Chem. 1996, in preparation).
- the rotation value for R-2b is:
- nitrile R-2b is converted into the primary amine by means of NaCNBH 3 , which is hydrogenated by standard hydrogenation at RT and under normal pressure for two hours on a Pd / C catalyst:
- Salmonella typhimurium 32), E. coli (30), Klebsiella pneumonia (33), Pseudomonas aeruginosa strain 6609 (34), strain 648 (30), strain 201 (32), strain K 437 (34).
- Myxochelin C and Myxochelin C R have antiviral activities against cytomegalon viruses from strain AD-169.
- the IC 50 values for the active substances are 0.7 ⁇ g / ml for myxochelin C and 1 ⁇ g / ml for myxochelin C B.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4447374A DE4447374A1 (de) | 1994-12-22 | 1994-12-22 | Myxochelin C und verwandte Verbindungen, neue Syntheseprodukte als Metalltransporteure und als chemo-therapeutische Mittel |
AU64172/96A AU6417296A (en) | 1994-12-22 | 1996-06-26 | Compounds which can form complexes with metals |
EP96923943A EP0923538A1 (de) | 1994-12-22 | 1996-06-26 | Verbindungen, die mit metallen komplexe bilden können |
PCT/EP1996/002796 WO1997049669A1 (de) | 1994-12-22 | 1996-06-26 | Verbindungen, die mit metallen komplexe bilden können |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4447374A DE4447374A1 (de) | 1994-12-22 | 1994-12-22 | Myxochelin C und verwandte Verbindungen, neue Syntheseprodukte als Metalltransporteure und als chemo-therapeutische Mittel |
PCT/EP1996/002796 WO1997049669A1 (de) | 1994-12-22 | 1996-06-26 | Verbindungen, die mit metallen komplexe bilden können |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997049669A1 true WO1997049669A1 (de) | 1997-12-31 |
Family
ID=42315199
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1996/002796 WO1997049669A1 (de) | 1994-12-22 | 1996-06-26 | Verbindungen, die mit metallen komplexe bilden können |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0923538A1 (de) |
AU (1) | AU6417296A (de) |
DE (2) | DE4447374A1 (de) |
WO (1) | WO1997049669A1 (de) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999042435A2 (de) * | 1998-02-21 | 1999-08-26 | Analyticon Ag Biotechnologie Pharmazie | Myxocheline |
DE19807475A1 (de) * | 1998-02-24 | 1999-09-09 | Analyticon Ag | Myxocheline |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4447374A1 (de) * | 1994-12-22 | 1996-06-27 | Trowitzsch Kienast Wolfram Pro | Myxochelin C und verwandte Verbindungen, neue Syntheseprodukte als Metalltransporteure und als chemo-therapeutische Mittel |
DE10111161A1 (de) * | 2001-03-01 | 2002-09-05 | Gruenenthal Gmbh | Neue Siderophoranaloga als 4- oder 6-zähnige Eisenchelatoren auf der Basis von Aminosäuren oder Peptiden, Verfahren zu ihrer Herstellung und ihre Anwendung |
DE102007008655A1 (de) * | 2007-02-20 | 2008-08-21 | Henkel Ag & Co. Kgaa | Siderophor-Metall-Komplexe als Bleichkatalysatoren |
WO2008151288A2 (en) * | 2007-06-05 | 2008-12-11 | Xenon Pharmaceuticals Inc. | Aromatic and heteroaromatic compounds useful in treating iron disorders |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07252197A (ja) * | 1994-03-13 | 1995-10-03 | Masayasu Akiyama | リジン残基を含むトリスカテコールアミド誘導体 |
DE4447374A1 (de) * | 1994-12-22 | 1996-06-27 | Trowitzsch Kienast Wolfram Pro | Myxochelin C und verwandte Verbindungen, neue Syntheseprodukte als Metalltransporteure und als chemo-therapeutische Mittel |
-
1994
- 1994-12-22 DE DE4447374A patent/DE4447374A1/de not_active Withdrawn
-
1996
- 1996-06-21 DE DE1996126020 patent/DE19626020A1/de not_active Withdrawn
- 1996-06-26 AU AU64172/96A patent/AU6417296A/en not_active Abandoned
- 1996-06-26 WO PCT/EP1996/002796 patent/WO1997049669A1/de not_active Application Discontinuation
- 1996-06-26 EP EP96923943A patent/EP0923538A1/de not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07252197A (ja) * | 1994-03-13 | 1995-10-03 | Masayasu Akiyama | リジン残基を含むトリスカテコールアミド誘導体 |
DE4447374A1 (de) * | 1994-12-22 | 1996-06-27 | Trowitzsch Kienast Wolfram Pro | Myxochelin C und verwandte Verbindungen, neue Syntheseprodukte als Metalltransporteure und als chemo-therapeutische Mittel |
Non-Patent Citations (6)
Title |
---|
AKIYAMA, MASAYASU ET AL: "Design and synthesis of artificial siderophores: lysine-based triscatecholate ligands as a model for enterobactin", CHEM. LETT. (1995), (9), 849-850 CODEN: CMLTAG;ISSN: 0366-7022, 1995, XP000617378 * |
BARELMANN, I. ET AL: "Cepaciachelin, a new catecholate siderophore from Burkholderia (Pseudomonas) cepacia", Z. NATURFORSCH., C: BIOSCI. (1996), 51(9/10), 627-630 CODEN: ZNCBDA;ISSN: 0341-0382, 1996, XP000617477 * |
DIARRA, M. S. ET AL: "Species selectivity of new siderophore-drug conjugates that use specific iron uptake for entry into bacteria", ANTIMICROB. AGENTS CHEMOTHER. (1996), 40(11), 2610-2617 CODEN: AMACCQ;ISSN: 0066-4804, 1996, XP000617329 * |
KUNZE, BRIGITTE ET AL: "Myxochelin A, a new iron-chelating compound from Angiococcus disciformis (Myxobacterales). Production, isolation, physico-chemical and biological properties", J. ANTIBIOT. (1989), 42(1), 14-17 CODEN: JANTAJ;ISSN: 0021-8820, 1989, XP000616420 * |
M. AUGUSTIN: "Cyclisierung von höheren DL-alpha-Aminocarbonsäurediestern und deren Dipeptidestern zu 2.5-Diketo-piperazinen.", CHEMISCHE BERICHTE, vol. 99, 1966, WEINHEIM DE, pages 1040 - 1048, XP000617382 * |
PATENT ABSTRACTS OF JAPAN vol. 95, no. 010 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999042435A2 (de) * | 1998-02-21 | 1999-08-26 | Analyticon Ag Biotechnologie Pharmazie | Myxocheline |
WO1999042435A3 (de) * | 1998-02-21 | 1999-12-16 | Analyticon Ag Biotechnologie P | Myxocheline |
DE19807475A1 (de) * | 1998-02-24 | 1999-09-09 | Analyticon Ag | Myxocheline |
Also Published As
Publication number | Publication date |
---|---|
DE4447374A1 (de) | 1996-06-27 |
AU6417296A (en) | 1998-01-14 |
DE19626020A1 (de) | 1998-01-02 |
EP0923538A1 (de) | 1999-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69532645T2 (de) | Heterozyklische pentapeptitische und halophenyl amide als hemmer für menschlichen krebs | |
DE2450355C2 (de) | ||
DE69532475T2 (de) | Krebs hemmende peptide | |
DE60003791T2 (de) | Felbamat-derivate | |
DE2440956C3 (de) | Kanamycin B-Derivate, Verfahren zu ihrer Herstellung und solche Derivate enthaltende Arzneimittel | |
DE69832987T2 (de) | Spingosinanaloga | |
DE69907419T2 (de) | Antitumorwirkstoffe | |
WO1999042435A2 (de) | Myxocheline | |
EP0923538A1 (de) | Verbindungen, die mit metallen komplexe bilden können | |
DE19507820A1 (de) | Neuartig substituierte DTPA-Derivate, deren Metallkomplexe, diese Komplexe enthaltende pharmazeutische Mittel, deren Verwendung in der Diagnostik, sowie Verfahren zur Herstellung der Komplexe und Mittel | |
DE3132221A1 (de) | Neue cyclophosphamid-derivate, verfahren zu ihrer herstellung und ihre verwendung | |
EP0863139B1 (de) | Benzoxazindionderivate, Verfahren zu ihrer Herstellung und ihre Verwendung | |
DE2618009A1 (de) | 1-n-(alpha-hydroxy-omega-aminoacyl)-derivate des 3'-deoxykanamycins a und verfahren zur herstellung derselben | |
DE2423591A1 (de) | 1-n-isoserylkanamycine | |
DE69917440T2 (de) | 5-Imino-13-desoxy-antracyclin-Derivate, ihre Verwendung sowie Verfahren zu deren Herstellung | |
DE60035154T2 (de) | Verbindungen zum spalten von doppelstrang-dns sowie verfahren zu deren verwendung | |
DE19807475A1 (de) | Myxocheline | |
DE69910810T2 (de) | Natriumsalz von 3-(4-cinnamyl-1-piperazinyl)-iminomethyl-rifamycin sv und verfahren zu seiner herstellung | |
DE2435619C3 (de) | ||
DE69829881T2 (de) | Synthetische antineoplastische wirkstoffe abgeleitet von dolastatin 15 sowie verfahren zu ihrer herstellung | |
EP3254679A1 (de) | Wirkstoffe gegen protozoen und bakterien | |
WO2002085841A2 (de) | Substituierte catecholderivate abgeleitet von mehrbasischen sekundären aminosäuren, verfahren zu ihrer herstellung und ihre anwendung | |
DE2950020A1 (de) | Neues verfahren zur herstellung von 1-n-isoseryl- oder 1-n-(l-4-amino-2-hydroxybutyryl)-3',4'-didesoxykanamycin b und dessen zeue zwischenstufen | |
DE3227178A1 (de) | 2'-modifizierte kanamycinderivate, verfahren zur herstellung derselben sowie mittel mit antibakterieller wirkung, die diese modifizierten kanamycinderivate enthalten | |
DE2855424A1 (de) | 2'-n-substituierte fortimicin a-derivate und ihre salze mit saeuren |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AU BB BG BR CA CN CZ DE EE GE HU IL IS JP KG KP KR LK LR LV MD MG MK MN MX NO NZ PL RO SG SI SK TR TT UA US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1996923943 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 97516877 Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 1996923943 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996923943 Country of ref document: EP |